StreetInsider.com News Articles

SciSparc shifts focus to agentic AI, forms advisory board

Mon, 27 Jul 2026 08:25:06 -0400

SciSparc Ltd. (Nasdaq: SPRC), a clinical-stage pharmaceutical company based in Tel Aviv, Israel, announced that its board of directors has decided to target the agentic artificial intelligence market.

As part of the initiative, the company said it is establishing a Scientific Advisory Board focused on AI and cybersecurity. SciSparc said it is currently evaluating opportunities and is in discussions with several companies active in the agentic AI field, though no specific agreements have been disclosed.

SciSparc currently operates through its majority-owned subsidiary NeuroThera, which is engaged in clinical-stage pharmaceutical development based on cannabinoid pharmaceuticals, including drug development programs using THC and CBD

SciSparc Announces Decision to Target the Agentic AI Market; Forms Scientific Advisory Board for Artificial Intelligence and Cybersecurity

Mon, 27 Jul 2026 08:25:00 -0400

TEL AVIV, Israel, July 27, 2026 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), today announced that its board of directors has made a decision to target the agentic artificial intelligence (“AI”) market.

As part of this initiative, the Company has decided to establish a Scientific Advisory Board to focus on AI and cybersecurity. SciSparc is currently evaluating opportunities and is in discussions with several companies active in the agentic AI field.

About SciSparc Ltd. (Nasdaq: SPRC):

The Company, through its majority-owned subsidiary NeuroThera, engages in clinical-stage pharmaceutical developments. SciSparc’s focus is

SciSparc Announces Decision to Target the Agentic AI Market; Forms Scientific Advisory Board for Artificial Intelligence and Cybersecurity

Mon, 27 Jul 2026 08:25:00 -0400

About SciSparc Ltd. (Nasdaq: SPRC):

The Company, through its majority-owned subsidiary NeuroThera, engages in clinical-stage pharmaceutical developments. SciSparc’s focus is

SciSparc Announces Decision to Target the Agentic AI Market; Forms Scientific Advisory Board for Artificial Intelligence and Cybersecurity

Mon, 27 Jul 2026 08:25:00 -0400

About SciSparc Ltd. (Nasdaq: SPRC):

The Company, through its majority-owned subsidiary NeuroThera, engages in clinical-stage pharmaceutical developments. SciSparc’s focus is

SciSparc Announces Decision to Target the Agentic AI Market; Forms Scientific Advisory Board for Artificial Intelligence and Cybersecurity

Mon, 27 Jul 2026 08:25:00 -0400

About SciSparc Ltd. (Nasdaq: SPRC):

The Company, through its majority-owned subsidiary NeuroThera, engages in clinical-stage pharmaceutical developments. SciSparc’s focus is

Form 6-K SciSparc Ltd. For: Jul 15

Wed, 15 Jul 2026 16:01:00 -0400

si-local-file:///var/storage/secattach/20260715/26774039.html

Form 6-K SciSparc Ltd. For: Jul 15

Wed, 15 Jul 2026 16:01:00 -0400

si-local-file:///var/storage/secattach/20260715/26774039.html

SciSparc: NeuroThera Labs Announces Initiation of Phase IIb Clinical Trial at Hannover Medical School in Germany for Innovative Treatment of Tourette Syndrome

Wed, 15 Jul 2026 08:41:00 -0400

TEL AVIV, Israel, July 15, 2026 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), today announced that its subsidiary NeuroThera Labs Inc. (TSXV: NTLX) ("NeuroThera"), a clinical-stage pharmaceutical company focused on developing novel treatments for central nervous system disorders, announced the initiation of its Phase IIb clinical trial site at Hannover Medical School, Hanover, Germany (“MHH”), for SCI-110, its proprietary cannabinoid-based treatment candidate for Tourette Syndrome (TS) in adults.

The trial, which previously received regulatory clearance from Germany’s Federal Institute for Drugs and Medical Devices and MHH's ethics committee, is now advancing towards

SciSparc: NeuroThera Labs Announces Initiation of Phase IIb Clinical Trial at Hannover Medical School in Germany for Innovative Treatment of Tourette Syndrome

Wed, 15 Jul 2026 08:41:00 -0400

The trial, which previously received regulatory clearance from Germany’s Federal Institute for Drugs and Medical Devices and MHH's ethics committee, is now advancing towards

SciSparc: NeuroThera Labs Announces Initiation of Phase IIb Clinical Trial at Hannover Medical School in Germany for Innovative Treatment of Tourette Syndrome

Wed, 15 Jul 2026 08:41:00 -0400

The trial, which previously received regulatory clearance from Germany’s Federal Institute for Drugs and Medical Devices and MHH's ethics committee, is now advancing towards

SciSparc: NeuroThera Labs Announces Initiation of Phase IIb Clinical Trial at Hannover Medical School in Germany for Innovative Treatment of Tourette Syndrome

Wed, 15 Jul 2026 08:41:00 -0400

The trial, which previously received regulatory clearance from Germany’s Federal Institute for Drugs and Medical Devices and MHH's ethics committee, is now advancing towards

Form 3/A SciSparc Ltd. For: Mar 18 Filed by: Adler Oz

Mon, 13 Jul 2026 07:08:00 -0400

si-local-file:///var/storage/secattach/20260713/26759659.html

Form 3/A SciSparc Ltd. For: Mar 18 Filed by: Adler Oz

Mon, 13 Jul 2026 07:08:00 -0400

si-local-file:///var/storage/secattach/20260713/26759659.html

Form 3/A SciSparc Ltd. For: Mar 18 Filed by: Revach Moshe

Mon, 13 Jul 2026 07:07:00 -0400

si-local-file:///var/storage/secattach/20260713/26759646.html

Form 3/A SciSparc Ltd. For: Mar 18 Filed by: Revach Moshe

Mon, 13 Jul 2026 07:07:00 -0400

si-local-file:///var/storage/secattach/20260713/26759646.html

Form 3/A SciSparc Ltd. For: Mar 18 Filed by: Shay Amnon Ben

Mon, 13 Jul 2026 07:06:00 -0400

si-local-file:///var/storage/secattach/20260713/26759636.html

Form 3/A SciSparc Ltd. For: Mar 18 Filed by: Shay Amnon Ben

Mon, 13 Jul 2026 07:06:00 -0400

si-local-file:///var/storage/secattach/20260713/26759636.html

Form 3/A SciSparc Ltd. For: Mar 18 Filed by: DAYAN ALON

Mon, 13 Jul 2026 07:05:00 -0400

si-local-file:///var/storage/secattach/20260713/26759633.html

Form 3/A SciSparc Ltd. For: Mar 18 Filed by: DAYAN ALON

Mon, 13 Jul 2026 07:05:00 -0400

si-local-file:///var/storage/secattach/20260713/26759633.html

Form 3/A SciSparc Ltd. For: Mar 18 Filed by: Sidi Liat

Mon, 13 Jul 2026 07:04:00 -0400

si-local-file:///var/storage/secattach/20260713/26759628.html

Form 3/A SciSparc Ltd. For: Mar 18 Filed by: Sidi Liat

Mon, 13 Jul 2026 07:04:00 -0400

si-local-file:///var/storage/secattach/20260713/26759628.html

Form 3/A SciSparc Ltd. For: Mar 18 Filed by: Weiss Amitay

Mon, 13 Jul 2026 07:03:00 -0400

si-local-file:///var/storage/secattach/20260713/26759620.html

Form 3/A SciSparc Ltd. For: Mar 18 Filed by: Weiss Amitay

Mon, 13 Jul 2026 07:03:00 -0400

si-local-file:///var/storage/secattach/20260713/26759620.html

Form 3/A SciSparc Ltd. For: Mar 18 Filed by: Vider Lior

Mon, 13 Jul 2026 07:02:00 -0400

si-local-file:///var/storage/secattach/20260713/26759609.html

Form 3/A SciSparc Ltd. For: Mar 18 Filed by: Vider Lior

Mon, 13 Jul 2026 07:02:00 -0400

si-local-file:///var/storage/secattach/20260713/26759609.html